Sutton Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Sutton Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14	Closed	-$1.67K	–	1284
2022 Q4	$1.67K	Hold	14	–	–	﹤0.01%	1231
2022 Q3	$1.49K	Hold	14	–	–	﹤0.01%	1222
2022 Q2	$1.36K	Sell	14 -149	-91%	-$13.8K	﹤0.01%	1227
2022 Q1	$15.3K	Buy	163 +3	+2%	+$254	0.01%	807
2021 Q4	$13.6K	Buy	160 +11	+7%	+$1.01K	﹤0.01%	829
2021 Q3	$14.3K	Hold	149	–	–	0.01%	799
2021 Q2	$14.5K	Hold	149	–	–	0.01%	795
2021 Q1	$14.5K	Hold	149	–	–	0.01%	767
2020 Q4	$14.3K	Hold	149	–	–	0.01%	706
2020 Q3	$14.3K	Hold	149	–	–	0.01%	642
2020 Q2	$18.2K	Hold	149	–	–	0.01%	563
2020 Q1	$12.9K	Hold	149	–	–	0.01%	585
2019 Q4	$16K	Hold	149	–	–	0.01%	684
2019 Q3	$13.4K	Hold	149	–	–	0.01%	708
2019 Q2	$12.6K	Hold	149	–	–	0.01%	723
2019 Q1	$13.1K	Hold	149	–	–	0.01%	713
2018 Q4	$10.6K	Hold	149	–	–	0.01%	729
2018 Q3	$18.3K	Hold	149	–	–	0.01%	621
2018 Q2	$14.6K	Hold	149	–	–	0.01%	719
2018 Q1	$12.4K	Hold	149	–	–	0.01%	751
2017 Q4	$11.6K	Buy	+149	New	+$10.2K	0.01%	735

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sutton Wealth Advisors's NBIX Position: Q1 2023 in Review

Sutton Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 14 shares — an estimated $1.67K sold.

Sutton Wealth Advisors first reported a position in NBIX in Q4 2017 and held it in 21 quarters. The position peaked at $18.3K in Q3 2018. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

Sutton Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
Sutton Wealth Advisors sold 14 Neurocrine Biosciences shares in Q1 2023, an estimated $1.67K.
Sutton Wealth Advisors first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 21 quarters.
Sutton Wealth Advisors's Neurocrine Biosciences position peaked at $18.3K in Q3 2018.
486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Sutton Wealth Advisors's 13F filing for Q1 2023, filed 7 Nov 2023.